To date prostate cancer diagnosis is widely based on prostate specific antigen (PSA) level testing and transrectal ultrasound (TRUS) guided biopsies, associated with a low specificity (PSA testing) or a low sensitivity (TRUS biopsies) resulting in high rates of rebiopsies. The gene discussed is KLK3; the disease is Familial prostate cancer.